Mainz Biomed B.V. (MYNZ)
USD 3.78
(-14.48%)
USD 3.78
(-14.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -25.01 Million USD | 3.84% |
| 2022 | -25.71 Million USD | -176.84% |
| 2021 | -11.28 Million USD | -3392.13% |
| 2020 | -257.64 Thousand USD | 61.13% |
| 2019 | -702.07 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -5.43 Million USD | 0.0% |
| 2023 Q1 | -6.2 Million USD | 22.2% |
| 2023 FY | - USD | 3.84% |
| 2023 Q2 | -7.75 Million USD | -25.08% |
| 2023 Q3 | -5.43 Million USD | 29.89% |
| 2022 Q4 | -7.96 Million USD | -47.51% |
| 2022 Q1 | -5.59 Million USD | 41.08% |
| 2022 Q3 | -5.4 Million USD | 20.87% |
| 2022 FY | - USD | -176.84% |
| 2022 Q2 | -6.82 Million USD | -21.99% |
| 2021 Q1 | -39.99 Thousand USD | 45.23% |
| 2021 FY | - USD | -3392.13% |
| 2021 Q4 | -9.49 Million USD | -235.58% |
| 2021 Q3 | -2.83 Million USD | -1075.64% |
| 2021 Q2 | -240.75 Thousand USD | -502.03% |
| 2020 Q1 | -73 Thousand USD | 60.24% |
| 2020 FY | - USD | 61.13% |
| 2020 Q4 | -73 Thousand USD | 0.0% |
| 2020 Q3 | -73 Thousand USD | 0.0% |
| 2020 Q2 | -73 Thousand USD | 0.0% |
| 2019 Q4 | -183.61 Thousand USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | -183.61 Thousand USD | 0.0% |
| 2019 Q2 | -183.61 Thousand USD | 0.0% |
| 2019 Q3 | -183.61 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 88.291% |
| Prenetics Global Limited | -47.89 Million USD | 47.78% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1382.585% |
| CareDx, Inc | -89.65 Million USD | 72.103% |
| Exact Sciences Corporation | 41.87 Million USD | 159.727% |
| Exagen Inc. | -19.15 Million USD | -30.586% |
| Inotiv, Inc. | -26.5 Million USD | 5.639% |
| Guardant Health, Inc. | -433.3 Million USD | 94.228% |
| Biodesix, Inc. | -37.1 Million USD | 32.59% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -906.422% |
| Precipio, Inc. | -4.31 Million USD | -479.231% |
| iSpecimen Inc. | -9.1 Million USD | -174.736% |
| Natera, Inc. | -383.27 Million USD | 93.474% |
| Aspira Women's Health Inc. | -16.49 Million USD | -51.666% |
| Standard BioTools Inc. | -54.45 Million USD | 54.072% |
| 23andMe Holding Co. | -291.87 Million USD | 91.431% |
| Castle Biosciences, Inc. | -45.02 Million USD | 44.449% |
| Personalis, Inc. | -96.8 Million USD | 74.164% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 78.726% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -160.777% |
| OpGen, Inc. | -29.51 Million USD | 15.248% |
| T2 Biosystems, Inc. | -43.87 Million USD | 42.994% |
| Myriad Genetics, Inc. | -67.8 Million USD | 63.11% |
| ICON Public Limited Company | 1.63 Billion USD | 101.533% |
| NeoGenomics, Inc. | -17.6 Million USD | -42.053% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1382.585% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 102.054% |
| RadNet, Inc. | 292.78 Million USD | 108.542% |
| MDxHealth SA | -30.46 Million USD | 17.91% |
| Psychemedics Corporation | -251 Thousand USD | -9864.623% |
| Illumina, Inc. | -608 Million USD | 95.886% |
| Check-Cap Ltd. | -17.64 Million USD | -41.715% |
| Twist Bioscience Corporation | -176.7 Million USD | 85.846% |
| DarioHealth Corp. | -53.49 Million USD | 53.245% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 46.273% |
| Sera Prognostics, Inc. | -35.28 Million USD | 29.121% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -155.613% |
| OPKO Health, Inc. | -65.51 Million USD | 61.824% |
| Medpace Holdings, Inc. | 363.15 Million USD | 106.887% |
| Neogen Corporation | 182.59 Million USD | 113.697% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -183.873% |
| Prenetics Global Limited | -47.89 Million USD | 47.78% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -227.831% |
| Trinity Biotech plc | -24.09 Million USD | -3.79% |
| Neuronetics, Inc. | -22.75 Million USD | -9.896% |
| Sotera Health Company | 514.14 Million USD | 104.865% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -227.831% |